+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030- Product Image
PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030- Product Image
Sale

PDGFR Inhibitor Market by Indication, Drug Type, Delivery Route, End User, Sales Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6016422
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The PDGFR Inhibitor Market is entering a pivotal phase as advances in targeted therapies, robust clinical innovation, and evolving regulatory frameworks reshape the landscape for senior executives and strategy leaders.

Market Snapshot: PDGFR Inhibitor Market

The PDGFR inhibitor market grew from USD 3.43 billion in 2024 to USD 3.60 billion in 2025 and is projected to reach USD 4.59 billion by 2030, reflecting a CAGR of 4.99%. Precision therapy targeting platelet-derived growth factor receptors is seeing strong clinical demand, with oncology and related indications creating sustained momentum for stakeholder investment and development. The market’s expansion is supported by technological advancement, global adoption, and evolving clinical guidelines that increasingly favor selective, patient-centric options.

Scope & Segmentation

This report delivers an in-depth analysis of the PDGFR inhibitor market, segmented by therapeutic area, drug type, delivery channel, end user, sales channel, region, and company. Segmentation provides actionable insights into underserved and high-potential sub-markets for organizations seeking to refine portfolio and go-to-market strategy.

  • Indications: Chronic myeloid leukemia, gastrointestinal stromal tumors
  • Drug Types: Monoclonal antibodies (fully human, humanized), small molecule inhibitors (first, second, and third generation)
  • Delivery Routes: Intravenous (infusion, injection), oral (capsule, tablet)
  • End Users: Ambulatory surgical centers, hospitals, specialty clinics
  • Sales Channels: Hospital pharmacies, online pharmacies, retail pharmacies
  • Regions: Americas (including U.S. with major states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with coverage of leading and emerging markets), Asia-Pacific (including China, India, Japan, Australia, South Korea, and others)
  • Key Companies: Novartis AG, Pfizer Inc., Bayer AG, Ipsen S.A., Exelixis, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim International GmbH

Key Takeaways

  • Advancement in PDGFR inhibitors has shifted the focus from broad chemotherapeutics to innovative therapies purpose-built for molecular targets, enhancing therapeutic precision across high-need diseases.
  • Next-generation engineering in both small molecules and monoclonal antibodies is driving increased selectivity, improved safety profiles, and minimized immunogenicity in treatment options.
  • Market stratification shows intravenous administration continues to dominate in-acute settings, while oral therapies are gaining ground for outpatient care and patient adherence, fueling ongoing formulation and patient-centric design innovations.
  • Clinical validation and investment remain highest in indications with demonstrable disease burden such as chronic myeloid leukemia, guiding priority-setting for R&D pipelines and regulatory filings.
  • PDGFR inhibitor manufacturers and service providers benefit from adaptive licensing frameworks and real-world evidence initiatives, with companion diagnostics increasingly used to optimize patient selection.
  • Different regional dynamics are shaping local adoption, from payer-driven value assessments in the Americas to customized market entry strategies in emerging EMEA and Asia-Pacific economies.

Tariff Impact

In 2025, newly implemented U.S. tariffs affecting active pharmaceutical ingredients and key manufacturing inputs prompted an increase in input costs for PDGFR inhibitor manufacturing and research. Mid-tier and smaller biotechs experienced higher overheads for laboratory supplies and animal models. In response, organizations shifted research and formulation work back to domestic sites, spurring vertical integration and driving consolidation among contract development and manufacturing organizations (CDMOs). While this created near-term financial pressure, it is also fostering stronger supply chain resilience and an expanded domestic manufacturing footprint.

Methodology & Data Sources

This report uses a comprehensive methodology combining primary interviews with oncologists, pharmacologists, payers, senior executives, and CRO leaders, allied with deep secondary research across scientific journals, regulatory filings, patents, and financials. Proprietary clinical trial tracking, scenario modeling, and real-world data underpin the strategic analyses.

Why This Report Matters

  • Enables senior leaders to understand the full spectrum of PDGFR inhibitor market dynamics, guiding more confident investment and resource allocation.
  • Provides actionable segmentation and competitive intelligence, empowering commercial and R&D teams to identify white space opportunities and anticipate shifts in regulatory or payer priorities.
  • Helps organizations navigate changing supply chain and policy environments, strengthening operational decision-making and risk management at the executive level.

Conclusion

The PDGFR inhibitor market is evolving through clinical innovation, global expansion, and adaptive strategies. Senior stakeholders who align technology, operations, and commercialization with these shifting trends will be best positioned to capture emerging opportunities and shape the future of targeted therapy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PDGFR Inhibitor Market, by Indication
8.1. Introduction
8.2. Chronic Myeloid Leukemia
8.3. Gastrointestinal Stromal Tumors
9. PDGFR Inhibitor Market, by Drug Type
9.1. Introduction
9.2. Monoclonal Antibody
9.2.1. Fully Human
9.2.2. Humanized
9.3. Small Molecule Inhibitor
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
10. PDGFR Inhibitor Market, by Delivery Route
10.1. Introduction
10.2. Intravenous
10.2.1. Infusion
10.2.2. Injection
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
11. PDGFR Inhibitor Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. PDGFR Inhibitor Market, by Sales Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas PDGFR Inhibitor Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa PDGFR Inhibitor Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific PDGFR Inhibitor Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Pfizer Inc.
16.3.3. Bayer AG
16.3.4. Ipsen S.A.
16.3.5. Exelixis, Inc.
16.3.6. Bristol-Myers Squibb Company
16.3.7. AstraZeneca PLC
16.3.8. Eli Lilly and Company
16.3.9. Merck & Co., Inc.
16.3.10. Boehringer Ingelheim International GmbH
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PDGFR INHIBITOR MARKET MULTI-CURRENCY
FIGURE 2. PDGFR INHIBITOR MARKET MULTI-LANGUAGE
FIGURE 3. PDGFR INHIBITOR MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PDGFR INHIBITOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PDGFR INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PDGFR INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PDGFR INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PDGFR INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PDGFR INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. CANADA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 59. CANADA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 60. CANADA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 61. CANADA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 62. CANADA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 63. CANADA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 114. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 115. GERMANY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 117. GERMANY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. GERMANY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 123. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 124. FRANCE PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 126. FRANCE PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 127. FRANCE PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. ITALY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. ITALY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 141. ITALY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 142. ITALY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ITALY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 144. ITALY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. ITALY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. SPAIN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 150. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 151. SPAIN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 153. SPAIN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 154. SPAIN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. DENMARK PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. DENMARK PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 186. DENMARK PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 187. DENMARK PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 189. DENMARK PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 190. DENMARK PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. QATAR PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. QATAR PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. QATAR PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 204. QATAR PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 205. QATAR PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 206. QATAR PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 207. QATAR PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 208. QATAR PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. FINLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 212. FINLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 213. FINLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 214. FINLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. FINLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. EGYPT PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 238. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 239. EGYPT PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 240. EGYPT PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 241. EGYPT PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. TURKEY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 247. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 248. TURKEY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 249. TURKEY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 250. TURKEY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 252. TURKEY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 253. TURKEY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. NORWAY PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 265. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. NORWAY PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 267. NORWAY PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 268. NORWAY PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 271. NORWAY PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. POLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 274. POLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 275. POLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 276. POLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 277. POLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 278. POLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 279. POLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 280. POLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. POLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 284. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 285. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 286. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 287. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 293. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 294. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 295. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 296. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC PDGFR INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 301. CHINA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. CHINA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 303. CHINA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 304. CHINA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 305. CHINA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 306. CHINA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 307. CHINA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 308. CHINA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. CHINA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. INDIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. INDIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 312. INDIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 313. INDIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 314. INDIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 315. INDIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 316. INDIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 317. INDIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. JAPAN PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 320. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 321. JAPAN PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 322. JAPAN PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 323. JAPAN PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 324. JAPAN PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 326. JAPAN PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. JAPAN PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 328. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 329. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 330. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 331. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 332. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 333. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 334. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 335. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 336. AUSTRALIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 341. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 342. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 343. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 344. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. SOUTH KOREA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 346. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 347. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 348. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 349. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 350. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 351. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 352. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 353. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 354. INDONESIA PDGFR INHIBITOR MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 355. THAILAND PDGFR INHIBITOR MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 356. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 357. THAILAND PDGFR INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 358. THAILAND PDGFR INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITOR, 2018-2030 (USD MILLION)
TABLE 359. THAILAND PDGFR INHIBITOR MARKET SIZE, BY DELIVERY ROUTE, 2018-2030 (USD MILLION)
TABLE 360. THAILAND PDGFR INHIBITOR MARKET SIZE, BY INTRAVEN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PDGFR Inhibitor market report include:
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Ipsen S.A.
  • Exelixis, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.59 Billion
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast to 2030 - Product Image

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, End User, Route Of Administration, Patient Age - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Specialty Pharmaceuticals Market by Therapeutic Area, Product Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Specialty Pharmaceuticals Market by Therapeutic Area, Product Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
RAGE Inhibitor - Pipeline Insight, 2025 - Product Image

RAGE Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
HPK1 Inhibitors - Pipeline Insight, 2025 - Product Image

HPK1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Feiba VH Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Feiba VH Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.